Skip to main content

Sanofi-Aventis S.A. ADR(SNY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low46.85
Day High47.54
Open:47.53
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
Motley Fool
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth
Zacks Investment Research
Merck Secures EU Nod for RSV Antibody Enflonsia in Infants
Merck Secures EU Nod for RSV Antibody Enflonsia in Infants
Tipranks
Sanofi’s Real‑World Teplizumab Study Targets Early Type 1 Diabetes Insights for Investors
Zacks Investment Research
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
Tipranks
Sanofi (SNYNF) Gets a Hold from Kepler Capital
Tipranks
Sanofi Builds Immunology Momentum with March 2026 Wave of Global Approvals and Data
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)
Tipranks
J.P. Morgan Sticks to Their Hold Rating for Sanofi (SNYNF)
Zacks Investment Research
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
Zacks Investment Research
Top Research Reports for Palantir, Linde and Arista Networks
Top Research Reports for Palantir, Linde and Arista Networks
Tipranks
Deutsche Bank Remains a Buy on Sanofi (SNYNF)
Tipranks
Jefferies Keeps Their Buy Rating on Sanofi (SNYNF)
Tipranks
Sanofi (SNYNF) Gets a Hold from J.P. Morgan
Zacks Investment Research
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Tipranks
Sanofi Wins FDA Breakthrough Therapy Status for Venglustat in Type 3 Gaucher Disease
GlobeNewswire
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
Tipranks
Sanofi Advances Early Autoimmune Antibody Program With New Phase 1 Study Update
Motley Fool
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?
Tipranks
Regeneron and Sanofi Extend Phase 3 Itepekimab Program in Chronic Sinus Disease
Tipranks
Dupilumab Study Tracks Mental Health Benefits in Atopic Dermatitis Patients Across Gulf Countries
Tipranks
Sanofi Targets Real-World Teplizumab Data in Type 1 Diabetes: What Investors Should Watch
Tipranks
Sanofi Wins Japan Orphan Status for Rilzabrutinib and Moves to Strengthen Governance
Zacks Investment Research
Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026?
Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026?
Tipranks
Sanofi Details CEO Paul Hudson’s February 2026 Departure Terms and Equity Awards
Zacks Investment Research
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
Zacks Investment Research
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
Motley Fool
The Best Healthcare Stock to Invest $1,000 in Right Now
Zacks Investment Research
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
Zacks Investment Research
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot
Tipranks
Sanofi’s New Pediatric Fitusiran Trial Signals a Long-Term Hemophilia Push
Tipranks
Sanofi Real-World Data Show Durable Two-Season Protection From Beyfortus in Infants

Profile

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.